Hoff LS, de Souza FHC, Miossi R, et al. - This study was undertaken to investigate the long-term effects of pulse intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIG) administered during the first year of diagnosis in dermatomyositis (DM) and polymyositis (PM) patients. Researchers designed a retrospective single-center cohort study including patients with DM/PM followed for up to 4 years from 2001 to 2017. Cox regression models were used to calculate hazard ratios (HRs) and evaluate the effects of early pulse IVMP or IVIG on 3 outcomes: complete clinical response, corticosteroid discontinuation, and survival. The study enrolled a total of 204 patients and classified them into 4 initial treatment groups: pulse IVMP (n = 46), pulse IVMP+IVIG (n = 55), IVIG (n = 10), and without IVMP or IVIG (n = 93). Patients with DM/PM submitted to pulse IVMP or pulse IVMP+IVIG during the first year of diagnosis had a higher HR for complete clinical response, despite having a more severe disease profile, whereas the combination of pulse IVMP+IVIG had a relationship with corticosteroid discontinuation. There is a need for prospective long-term studies to confirm these benefits of early pulse IVMP and IVIG on patients with DM/PM.